Inhibitor Therapeutics (INTI) Long-Term Debt Issuances (2013 - 2023)
Inhibitor Therapeutics' (INTI) quarterly Long-Term Debt Issuances came in at $411000.0 in Q1 2023, up 722.0% YoY from $50000.0 in Q1 2022, and up 413.75% on a QoQ basis from $80000.0 in Q3 2022.
Inhibitor Therapeutics (INTI) Long-Term Debt Issuances (2013 - 2023) Analysis & Trends
Inhibitor Therapeutics (INTI) has 6 years of Long-Term Debt Issuances data on file, last reported at $411000.0 in Q1 2023.
- Quarterly Long-Term Debt Issuances rose 722.0% year-over-year to $411000.0 in Q1 2023, while the trailing twelve-month figure through Dec 2023 was $411000.0 (up 128.33% YoY) and the FY2023 annual result came in at $411000.0, up 128.33% from the prior year.
- Long-Term Debt Issuances advanced to $411000.0 in Q1 2023, from $80000.0 in the prior quarter.
- In the past five years, Long-Term Debt Issuances ranged from a high of $411000.0 in Q1 2023 to a low of $41600.0 in Q3 2020.
- A 4-year average of $115514.3 and a median of $75000.0 in 2021 frame the typical range for Long-Term Debt Issuances.
- Annual changes were most pronounced in 2022 — Long-Term Debt Issuances plunged 50.5% — and 2023, when it surged 722.0%.
- Tracing INTI's Long-Term Debt Issuances over 4 years: stood at $41600.0 in 2020, then surged by 80.29% to $75000.0 in 2021, then advanced by 6.67% to $80000.0 in 2022, then soared by 413.75% to $411000.0 in 2023.
- The last three Long-Term Debt Issuances figures came in at $411000.0 (Q1 2023), $80000.0 (Q3 2022), and $50000.0 (Q2 2022), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Inhibitor Therapeutics | 15.64 Mn | 15.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2023 | 411,000.00 |
| Mar 31, 2023 | 411,000.00 |
| Sep 30, 2022 | 80,000.00 |
| Sep 30, 2022 | 80,000.00 |
| Jun 30, 2022 | 50,000.00 |
| Jun 30, 2022 | 50,000.00 |
| Mar 31, 2022 | 50,000.00 |
| Mar 31, 2022 | 50,000.00 |
| Jun 30, 2021 | 75,000.00 |
| Jun 30, 2021 | 75,000.00 |
| Mar 31, 2021 | 101,000.00 |
| Mar 31, 2021 | 101,000.00 |
| Sep 30, 2020 | 41,600.00 |
| Sep 30, 2020 | 41,600.00 |
| Dec 31, 2014 | 210,388.00 |
| Dec 31, 2014 | 210,388.00 |
| Sep 30, 2014 | -210,388.00 |
| Sep 30, 2014 | -210,388.00 |
| Jun 30, 2014 | 164,894.00 |
| Jun 30, 2014 | 164,894.00 |